Skip to main content
Quest Diagnostics

Blockade of the Mineralocorticoid Receptor Improves Markers of Human Endothelial Cell Dysfunction and Hematological Indices in a Mouse Model of Sickle Cell Disease

Blockade of the Mineralocorticoid Receptor Improves Markers of Human Endothelial Cell Dysfunction and Hematological Indices in a Mouse Model of Sickle Cell Disease

Authors: Rivera A, Vega C, Ramos-Rivera A, Maldonado ER, Prado GN, Karnes HE, Fesko YA, Snyder LM, Alper SL, Romero JR.

Citation: FASEB J. 2023 Aug;37(8):e23092. doi: 10.1096/fj.202300671R

Specialties: Oncology, Hematology, Coagulation

Relateed content

Publication
Trpv1 and Trpa1 are not essential for Psickle-like activity in red cells of the SAD mouse model of sickle cell disease
Publication
Purinergic signaling is essential for full Psickle activation by hypoxia and by normoxic acid pH in mature human sickle red cells and in vitro-differentiated cultured human sickle reticulocytes

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.